AndreaLSitlingerMD

PubMed

• 107 citations
  Health-Related Quality of Life: The Impact on Morbidity and Mortality.
  Andrea Sitlinger, Syed Yousuf Zafar
  Surgical Oncology Clinics of North America. 2018-07-21
• 30 citations
  Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
  Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel
  Blood. 2021-05-20
• 22 citations
  Cardiometabolic Comorbidities in Cancer Survivors:State-of-the-Art Review.
  Leah L Zullig, Anthony D Sung, Michel G Khouri, Shelley Jazowski, Nishant P Shah
  JACC. Cardiooncology. 2022-06-01

Abstracts/Posters

• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Andrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Andrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
  Andrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Andrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cancer- Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina
  Andrea Sitlinger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all